Background: Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.
Methods: A total of 91 infants with CHD who received palivizumab prophylaxis and 96 infants with CHD without prophylaxis (0-12 months:52; 12-24 months:44) were included in this single-center retrospective case control study. Data on patient characteristics, household environment, and LRTIs were evaluated.
Results: In patients without prophylaxis, the rate of overall lower respiratory tract infections (LRTIs) (P < 0.001), complicated LRTIs (P = 0.006), LRTI-related hospitalization (P < 0.001) and ICU admission (P = 0.008) were significantly higher than control patients. Weight <10th percentile (odds ratio (OR) 5.78, 95% confidence interval (CI):1.37; 24.4, P < 0.001) and concomitant chromosome abnormality (OR 4.01, 95% CI:1.01;16.45, P < 0.001) in patients with prophylaxis, while presence of a sibling <11 years of age (OR 3.38, 95% CI: 1.21; 9.46, P < 0.001) and congestive heart failure (OR 8.63, 95% CI: 2.81; 26.6, P < 0.001) in the control group were the significant correlates of LRTI-related hospitalization.
Conclusion: Our findings revealed significantly lower rate of overall and complicated LRTIs, LRTI-related hospitalization and ICU admissions in infants with CHD via palivizumab prophylaxis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ppul.23102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Benefits of home-based administration of palivizumab in high-risk groups].
Andes Pediatr
August 2024
Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.
Unlabelled: Palivizumab, a humanized monoclonal antibody against the respiratory syncytial virus (RSV), currently is indicated in groups at higher risk of developing severe RSV disease, such as extreme premature infants and patients with hemodynamically significant heart disease. In Chile, this strategy is guaranteed by Law 20850 (Ricarte Soto Law). Nevertheless, barriers to its administration included the need to transfer these labile patients and exposure to other users, with the risk of contagion in waiting rooms.
View Article and Find Full Text PDFEvolving Strategies for Respiratory Syncytial Virus (RSV): A Review Article of Preventive Agents and Vaccines for RSV.
Ann Pharmacother
January 2025
ForHealth Consulting, UMass Chan Medical School, Shrewsbury, MA, USA.
Objective: The objective was to describe the pharmacology, efficacy, safety, and recommendations for the use of newly approved preventive agents and vaccines for respiratory syncytial virus (RSV) and discuss their uptake during the 2023 to 2024 RSV season.
Data Sources: A literature search of PubMed was performed (January 2020 to February 2024) with the search terms RSV vaccine, preventive antibody, and RSV prevention. Utilization data were collected from TriNetX using the US Collaborative Network (May 2024) using the terms palivizumab, nirsevimab, and RSV prefusion F protein.
Trends in endemic of respiratory syncytial virus infection during COVID-19 pandemic and difficulty in obtaining optimal timing of palivizumab prophylaxis.
J Infect Chemother
December 2024
Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; General Medical Department, Fukuoka Children's Hospital, Fukuoka, Japan. Electronic address:
Objective: The coronavirus disease (COVID-19) pandemic has affected the epidemiology of respiratory syncytial virus (RSV) infection. This study assessed whether or not palivizumab prophylaxis was appropriate during the COVID-19 pandemic.
Methods: This prospective study included children <24 months old who were hospitalized for RSV infection between April 2019 and March 2023.
[Not Available].
Can Fam Physician
December 2024
Conseillère médicale principale au Centre de surveillance et des programmes d'immunisation à l'Agence de la santé publique du Canada, professeure agrégée à la Section des allergies et de l'immunologie clinique du Département de pédiatrie à l'Université du Manitoba à Winnipeg, et professeure adjointe à la Division des allergies et de l'immunologie du Département de pédiatrie de l'Université de la Colombie-Britannique à Vancouver.
Approach to prevention of respiratory syncytial virus disease in infants by passive immunization.
Can Fam Physician
December 2024
Senior Medical Advisor in the Centre for Immunization Surveillance and Programs at the Public Health Agency of Canada, Associate Professor in the Department of Pediatrics in the Section of Allergy and Clinical Immunology at the University of Manitoba in Winnipeg, and Adjunct Professor in the Department of Pediatrics in the Division of Allergy and Immunology at the University of British Columbia in Vancouver.
Article Synopsis
- The objective is to help family physicians effectively discuss RSV immunizations with their patients.
- There are three preventive options for severe RSV disease in infants: palivizumab for high-risk infants, nirsevimab for all infants, and the RSVpreF vaccine for pregnant individuals.
- Family doctors need to understand each immunization option's specifics, including recommendations and patient considerations, to support informed choices for parents and infants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!